Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum
United Therapeutics Europe Ltd
Frostbite
1 trial -
Sulfato de Magnesio Altan 150 mg/ml soluciΓ³n inyectable y para perfusiΓ³n EFG, LIDOCAINE HYDROCHLORIDE, Dexdor 100 micrograms/ml concentrate for solution for infusion, KETOLAR 50 mg/ml soluciΓ³n inyectable.
The George Institute
Obesity
1 trial -
Tranexamic Acid 1000 mg/10ml normal saline infusion
United Therapeutics Europe Ltd
Postpartum Hemorrhage
1 trial -
Ultomiris 300 mg/30 mL concentrate for solution for infusion
The George Institute
IgA nephropathy
1 trial -
Ultomiris 300 mg/30 mL concentrate for solution for infusion
Disc Medicine
Paroxysmal nocturnal hemoglobinuria (PNH)
1 trial -
VYEPTI 100 mg concentrate for solution for infusion
H. Lundbeck A/S
Chronic Migrane, Migrane, Medication Overuse Headache
1 trial -
Vyvgart 20 mg/mL concentrate for solution for infusion
The George Institute
Patients affected by generalized myasthenia gravis
1 trial -
hylenex-facilitated subcutaneous Lactated Ringer's infusion
HALOZYME THERAPEUTICS, INC.
Dehydration
1 trial -
intravenous tranexamic acid (TXA) infusion
The First People's Hospital of Lianyungang
Spontaneous Intracranial Hemorrhage
1 trial -
A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
The First People's Hospital of Lianyungang
Neuromuscular Blockade
1 trial -
Abciximab local infusion
Atrium Therapeutics
Acute Anterior Myocardial Infarction
1 trial -
CD19 CAR-T cells infusion
The First People's Hospital of Lianyungang
Non Hodgkin Lymphoma
1 trial -
LCAR- F33S cells intravenous infusion
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Multiple Myeloma(MM)
1 trial -
intraileal infusion
The First People's Hospital of Lianyungang
Incretins
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources